Clostridioides difficile (C. difficile) infection is an intestinal disease. Our company is committed to pushing the boundaries of C. difficile diagnosis through state-of-the-art technologies and customized solutions. Through the development of innovative IVD reagents/kits and compact diagnostic devices, our goal is to tackle the intricacies of C. difficile pathogenesis and diagnostic hurdles, fundamentally reshaping the detection and control of this infectious disease.
Introduction to Clostridioides Difficile Infection
Clostridioides difficile (C. difficile) infection poses a significant threat to public health, causing a range of gastrointestinal symptoms from mild diarrhea to severe colitis. The bacterium, known for its ability to thrive in hospital environments, particularly affects individuals on antibiotic therapy by disrupting the normal gut microbiota balance. The incidence of C. difficile infections has been on the rise globally, prompting the need for advanced diagnostic tools for timely and accurate detection.
Fig. 1 Transmission of Clostridium difficile. (Lim S C, et al., 2020)
Diagnostic Biomarkers for Clostridioides Difficile Infection
C. difficile infection is a significant healthcare concern globally, necessitating accurate and timely diagnostic approaches for effective management. The identification of specific biomarkers associated with C. difficile infection can enhance diagnostic precision, facilitate early intervention, and improve outcomes of affected individuals.
Toxins A and B are primary virulence factors produced by C. difficile, contributing to the pathogenesis of infection. Enzyme immunoassays targeting toxins A and B in stool samples are commonly used for C. difficile diagnosis.
Toxins A and B
Glutamate dehydrogenase (GDH) is a highly conserved enzyme found in C. difficile and is used as a screening marker due to its high sensitivity. GDH assays are rapid and sensitive, aiding in the initial detection of C. difficile antigens.
Glutamate Dehydrogenase (GDH)
Different ribotypes of C. difficile exhibit varying virulence and antimicrobial resistance profiles. Ribotyping helps in tracking outbreaks, understanding epidemiology, and predicting therapeutic responses based on strain differences.
Ribotype
Common IVD Kits for Clostridioides Difficile Infection
In vitro diagnostic (IVD) kits for C. difficile infection play a pivotal role in the accurate and timely detection of this challenging healthcare concern. These kits are designed to provide reliable and rapid diagnostic tools to aid in the management of C. difficile infections.
| Kits |
Applications |
Detection Methods |
| Clostridioides Difficile Nucleic Acid Detection Kit |
Qualitative detection of C. difficile genetic material. |
PCR |
| Toxins A and B Detection Kit |
Detection and differentiation of C. difficile toxins A and B in stool samples. |
Enzyme Immunoassays (EIAs) |
| Glutamate Dehydrogenase (GDH) Detection Kit |
GDH assays are often used as a screening test due to their high sensitivity for detecting C. difficile antigens. |
ELISA |
Our Services
Our company excels in the provision of diagnostic development services tailored for Clostridioides difficile infection, offering a wide array of IVD solutions to address intricate diagnostic requirements. Our expertise lies in designing nucleic acid, antigen, metabolite or microbial detection reagents/kits specifically for Clostridioides difficile infection to enable early identification and accurate diagnosis of this serious infectious disease. Leveraging cutting-edge diagnostic devices, our primary goal is to streamline and automate the diagnostic procedures, ultimately enhancing operational efficiency.
IVD Product Development Services
Optional IVD Products
- Clostridioides Difficile Nucleic Acid Detection Kit
- Toxins A (tcdA) and B (tcdB) Detection Kit
- Glutamate Dehydrogenase (GDH) Detection Kit
- Clostridioides Difficile Ribotype Kit
- Clostridioides Difficile Quantitative Detection Kit
- Nucleic Acid Extraction Reagents
- PCR Reagents
- And More
To achieve rapid detection of Clostridium difficile infection, we offer point-of-care testing (POCT) development services committed to creating portable and user-friendly diagnostic tools. Our companion diagnostic development services aim to customize personalized care strategies by identifying biomarkers associated with therapeutic response, promoting precision medicine.
If you are interested in our services, please don't hesitate to reach out to us for further information and pricing details on the services we offer.
Reference
- Lim S C, Knight D R, Riley T V. Clostridium difficile and one health[J]. Clinical Microbiology and Infection, 2020, 26(7): 857-863.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
